Clinical Trial Update: A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the safety and efficacy of FF-10832 in combination with pembrolizumab for advanced urothelial carcinoma and advanced no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Urothelial Carcinoma

Drugs mentioned

• FF-10832
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. | Conditions: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING